Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$839M |
| 2 |
Amazon
AMZN
|
+$810M |
| 3 |
Tesla
TSLA
|
+$644M |
| 4 |
TSMC
TSM
|
+$546M |
| 5 |
Johnson & Johnson
JNJ
|
+$389M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$891M |
| 2 |
Home Depot
HD
|
+$441M |
| 3 |
JPMorgan Chase
JPM
|
+$335M |
| 4 |
NVO
Novo Nordisk
NVO
|
+$317M |
| 5 |
ASML
ASML
|
+$315M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 20.84% |
| 2 | Technology | 15.57% |
| 3 | Consumer Discretionary | 11.88% |
| 4 | Consumer Staples | 10.09% |
| 5 | Financials | 9.84% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
EARN
1826
Ellington Residential Mortgage REIT
EARN
$165M
| $2.97M | ﹤0.01% |
433,100
-38,000
| -8% | -$261K |
|
|
OPNT
1827
DELISTED
Opiant Pharmaceuticals, Inc. Common Stock
OPNT
| $2.97M | ﹤0.01% |
146,415
-30,500
| -17% | -$468K |
|
|
DCH
1828
Dauch Corp
DCH
$1.6B
| $2.96M | ﹤0.01% |
378,900
-123,600
| -25% | -$1.11M |
|
1829
LPL Financial
LPLA
$29.2B
| $2.96M | ﹤0.01% |
+13,700
| New | +$3.2M |
|
1830
Stepan Co
SCL
$1.48B
| $2.96M | ﹤0.01% |
27,800
-21,500
| -44% | -$2.25M |
|
1831
ProShares Short 20+ Year Treasury ETF
TBF
$107M
| $2.96M | ﹤0.01% |
130,400
-59,400
| -31% | -$1.34M |
|
1832
JD.com
JD
$39.2B
| $2.95M | ﹤0.01% |
52,600
+17,000
| +48% | +$855K |
|
|
STKL
1833
DELISTED
SunOpta
STKL
| $2.95M | ﹤0.01% |
349,038
-298,558
| -46% | -$2.82M |
|
1834
Invesco Variable Rate Preferred ETF
VRP
$3.01B
| $2.94M | ﹤0.01% |
+131,500
| New | +$2.92M |
|
1835
Acme United Corp
ACU
$232M
| $2.94M | ﹤0.01% |
134,307
-9,300
| -6% | -$221K |
|
1836
Marcus Corp
MCS
$925M
| $2.94M | ﹤0.01% |
204,400
+27,100
| +15% | +$410K |
|
1837
Alerian MLP ETF
AMLP
$13.2B
| $2.93M | ﹤0.01% |
76,900
+19,800
| +35% | +$778K |
|
|
BNFT
1838
DELISTED
Benefitfocus, Inc.
BNFT
| $2.93M | ﹤0.01% |
279,754
+194,454
| +228% | +$1.75M |
|
|
CNCE
1839
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
| $2.92M | ﹤0.01% |
500,605
-142,000
| -22% | -$747K |
|
1840
iShares National Muni Bond ETF
MUB
$45.8B
| $2.92M | ﹤0.01% |
+27,700
| New | +$2.89M |
|
|
IMGO
1841
DELISTED
Imago BioSciences, Inc. Common stock
IMGO
| $2.92M | ﹤0.01% |
+81,300
| New | +$2.03M |
|
1842
Crawford & Co Class A
CRD.A
$632M
| $2.92M | ﹤0.01% |
525,524
-33,300
| -6% | -$202K |
|
|
LGF.A
1843
DELISTED
Lions Gate Entertainment Corp. Class A Voting Shares
LGF.A
| $2.92M | ﹤0.01% |
511,378
-147,800
| -22% | -$1.04M |
|
1844
Embecta
EMBC
$289M
| $2.9M | ﹤0.01% |
114,800
+7,300
| +7% | +$223K |
|
1845
Highwoods Properties
HIW
$3.48B
| $2.9M | ﹤0.01% |
103,600
-62,500
| -38% | -$1.74M |
|
1846
Caleres
CAL
$449M
| $2.9M | ﹤0.01% |
129,950
+40,100
| +45% | +$984K |
|
1847
Home BancShares
HOMB
$6.28B
| $2.89M | ﹤0.01% |
+126,639
| New | +$3.07M |
|
|
HEES
1848
DELISTED
H&E Equipment Services
HEES
| $2.88M | ﹤0.01% |
63,400
-54,132
| -46% | -$2.1M |
|
1849
Oil States International
OIS
$539M
| $2.88M | ﹤0.01% |
385,800
-311,786
| -45% | -$1.93M |
|
|
RTL
1850
DELISTED
The Necessity Retail REIT, Inc. Class A Common Stock
RTL
| $2.87M | ﹤0.01% |
484,020
+229,920
| +90% | +$1.46M |
|
Similar funds
Jim Simons's Q4 2022 Portfolio in Review
As of Q4 2022, Jim Simons held 4,601 positions worth $73.1B, up 3.4% from $70.7B the previous quarter. Its ten largest holdings account for 11% of the portfolio.
Jim Simons's Q4 2022 filing shows 626 new, 1,390 increased, 2,018 reduced and 524 closed positions. Its largest new stake was Johnson & Johnson: 2,254,125 shares worth $398M. The largest sale was Microsoft, an estimated $891M.
By sector, the portfolio is most concentrated in Healthcare at 21% of assets, up from 19% a quarter earlier, followed by Technology and Consumer Discretionary.
- Jim Simons's largest Q4 2022 buy was Johnson & Johnson: 2,254,125 shares worth $398M.
- Jim Simons added most to Apple in Q4 2022, an estimated $839M increase.
- Jim Simons's biggest Q4 2022 reduction was Novo Nordisk, cutting an estimated $317M.
- Jim Simons fully exited Microsoft in Q4 2022, selling an estimated $891M.
- Jim Simons's ten largest holdings make up 11% of its $73.1B portfolio in Q4 2022.
- Jim Simons opened 626 new positions and closed 524 in Q4 2022.
- Jim Simons's portfolio value rose 3.4% quarter-over-quarter to $73.1B.
Based on Renaissance Technologies's 13F filing for Q4 2022, filed 13 Feb 2023.